BET inhibitors, a class of drugs already in clinical trials, might work especially well in breast cancer patients who have acquired a Y537S mutation, according to a preclinical study led by researchers at UT Southwestern Medical Center.
Organon launched the distribution of Ontruzant, a biosimilar of Herceptin, in Canada, providing an additional treatment option for Canadian adults diagnosed with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Shortly after Craig Jordan finished his PhD in the 1970s, he was invited by Michael Harper to work at the Worcester Foundation, the “home of the oral contraceptive.”
Jeannie Shen was appointed medical director of the Breast Program at Huntington Hospital, an affiliate of Cedars-Sinai, and medical director of the International Health Program at Cedars-Sinai Cancer at Huntington Hospital.
The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid, and Novartis AG are joining and committing resources to improve outcomes for people living with HR+/HER2- advanced breast care in low- and middle-income countries.
Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.
Through a genomic screening method known as CRISPR/CAS9 screening, Massey scientists—led by Anthony Faber and Jennifer Koblinski—identified a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target in triple negative breast cancer. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.
An analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to three involved lymph nodes and a 21-gene recurrence score of 25 or less found that rates of locoregional recurrence of the disease were low regardless of whether a patient had received regional node irradiation. The results suggest that a randomized clinical trial is required to answer the question of whether these favorable-risk patients can safely skip RNI.
MD Anderson Cancer Center and World Health Organization formed an agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the two institutions to further promote their shared efforts in advancing global cancer initiatives in women’s cancers, including breast and cervical cancers.
New research indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will metastasize to the brain.
